Dr. Gomella on Using Novel Biomarkers to Inform Biopsy Vs Observation in Prostate Cancer
Leonard G. Gomella, MD, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.
EP: 1.Sidney Kimmel Cancer Center at Thomas Jefferson University Stands Out
EP: 2.Dr. Gomella on Using Novel Biomarkers to Inform Biopsy Vs Observation in Prostate Cancer
EP: 3.Dr. Lipson on the Role of ctDNA Testing in Melanoma
EP: 4.Lipson Sheds Light on the Evolving Role of ctDNA in the Realm of Melanoma
EP: 5.Brahmer Discusses Influence of 5-Year Nivolumab and Ipilimumab OS Data in Metastatic NSCLC
EP: 6.Dr. Seedor on Treatment Sequencing in Metastatic Melanoma
EP: 7.Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer
Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.
Urine and blood markers identified with tools such as the SelectMDx urine test, ExosomeDx test, and 4Kscore® test can be used in the early detection of men with prostate cancer, says Gomella. Rather than diagnosing prostate cancer, these tests can provide additional data points to inform whether a patient who has an elevated prostate-specific antigen should undergo a biopsy or continue with active surveillance, Gomella explains.
Additionally, although MRI was not thought to be a relevant tool in prostate cancer, combining these novel clinical tests with MRI could increase the likelihood of identifying clinically relevant prostate cancer, Gomella says. However, a concern is that clinically unimportant cancers could also be identified, so the field is learning how to best determine which patients should undergo a biopsy, concludes Gomella.
